When the molecular subtypes were divided into those with low and high levels of isoform expression relative to the median, it was found that 86% of the patients with HER2+ and HLA-G6 low tumours had a pCR, in comparison with only 46% in the high-level HLA-G6 group (Table 4). Here, ERBB2 is linked to neoplasm.